Trusted Medical Care
At the Seoul National University Cancer Hospital Hematologic Malignancy Center, we provide specialized care not only for various blood cancers including acute and chronic leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms, but also for a wide spectrum of non-malignant hematologic diseases. These include aplastic anemia, iron deficiency anemia, hemolytic anemia, immune thrombocytopenia, hemophilia, and thrombotic disorders such as venous thrombosis.
To ensure the most effective treatment for these complex conditions, we collaborate closely with experts in laboratory medicine, nuclear medicine, radiology, and pathology. The Center is equipped with Korea’s leading facilities, including a state-of-the-art blood bank, cellular immunology laboratory, genomic testing facilities, and hematopoietic stem cell transplantation (HSCT) unit, enabling us to deliver advanced and highly specialized therapies. Our comprehensive treatment portfolio includes Chimeric Antigen Receptor (CAR)-T cell therapy, therapies utilizing blood and cellular products, therapeutic apheresis, as well as a wide range of transplants such as autologous, umbilical cord blood, and haploidentical HSCT. In addition, by leveraging genomic profiling services specific to hematologic malignancies, we provide precision medicine tailored to each patient.
A Global Research-Driven Hospital
In recent years, research on molecular targeted agents and cell therapies for hematologic malignancies has been rapidly accelerating, accompanied by a sharp increase in related clinical trials. To meet this demand, the Hematologic Malignancy Center actively leads clinical trials including “First-in-Human” studies on novel drugs and next-generation cellular therapies, spearheading innovations in blood cancer treatment. We also play a pivotal role in cancer genomics research, participating since 2013 in the International Cancer Genome Consortium (ICGC) as the designated research institution responsible for hematologic malignancy genomics. Indeed, our physician-scientists have published groundbreaking work in the world’s leading journals including Blood, the most authoritative journal in hematology, earning international recognition for their scientific achievements. In addition, research professors specializing exclusively in hematologic malignancies work in close collaboration with physician-scientists through the Seoul National University Cancer Research Institute, conducting world-class basic and translational research. Building on this robust research infrastructure and internationally recognized achievements, the Center is committed to providing patients with relapsed or refractory hematologic malignancies, who often face limited options with conventional therapies, expanded opportunities to access novel drugs and cellular therapies. In doing so, the Hematologic Malignancy Center fulfills its mission as a research-driven hospital of global excellence.
Extensive Experience in Hematopoietic Stem Cell Transplantation and CAR-T Therapy
The Hematopoietic Stem Cell Transplantation Center at Seoul National University Cancer Hospital is Korea’s leading transplant center, having performed more than 3,400 transplants by 2023. Our expertise spans autologous transplantation, matched sibling and unrelated donor transplantation, as well as highly complex procedures including second transplants, haploidentical transplants, cord blood transplants, and cell-separated transplants. Since 2022, we have also been at the forefront of CAR-T cell therapy, treating patients with relapsed or refractory lymphoma and acute lymphoblastic leukemia. In addition, we are actively conducting clinical trials of novel CAR-T therapies for multiple myeloma, further expanding our leadership in cellular immunotherapy in Korea. Hematopoietic stem cell transplantation and CAR-T therapy represent the ultimate curative options for patients with relapsed or refractory blood cancers, yet they are also highly complex and high-risk procedures. For this reason, success relies on a well-organized transplant infrastructure and the extensive expertise of a dedicated medical team. The HSCT team at Seoul National University Cancer Hospital embodies all of these qualities, providing world-class care as Korea’s premier transplant program.
Trustworthy medical team
The Hemato-Oncology Center of the Seoul National University Cancer Hospital provides specialized care for hematologic malignancies such as chronic leukemia, multiple myeloma, malignant lymphoma, myelodysplastic syndrome, and myeloproliferative diseases, as well as hemorrhagic and thromboembolic diseases including aplastic anemia, deficiency anemia, hemolytic anemia, hemophilia, and venous thrombosis.
Our center delivers the best treatment results by cooperating with top-class experts in related fields for the effective treatment of hematologic malignancies and blood diseases with complex characteristics. To provide accurate diagnoses and monitor treatment responses, we work closely with the Laboratory Medicine Department, Nuclear Medicine Department, Radiology Department, and Pathology Department and perform treatments that require a high level of skills such as hematopoietic stem cell transplantation, which includes treatments with blood and cell products, apheresis, and cord blood/haploidentical transplantation. We provide customized cancer treatment by using our hematologic gene sequencing service, which is the basis of every customized treatment.
World-class research-centered hospital
Recently, research on molecular targeted therapy and cell therapy products is rapidly increasing, and clinical trials using new drugs/technologies are also quickly increasing. Accordingly, the Hemato-Oncology Center at Seoul National University Cancer Hospital is leading the research on hematological malignancy by conducting clinical trials on various new drugs and cell therapy products for hematologic malignancies including the “first in human trials.” We have also been participating in the International Cancer Genome Consortium (ICGC), which is the largest global cooperative researcher in the field of the cancer genome as a research institute responsible for the genome in the field of hematologic malignancy since 2013. Expanding the clinical trial opportunities to recurrent/intractable hematologic malignancy patients whose treatment options are limited is also one of the missions of the Hemato-Oncology Center at Seoul National University Cancer Hospital.
Rich experience in hematopoietic stem cell transplantation
The Hematopoietic Stem Cell Transplantation Center at Seoul National University Cancer Hospital is the best in Korea with more than 3,500 hematopoietic stem cell transplantation cases as of 2024. The center has accumulated experience in hematopoietic stem cell transplantations that require a high level of skills such as secondary hematopoietic stem cell transplantation, haploidentical transplantation, cord blood transplantation, and cell separation transplantation in addition to autologous hematopoietic stem cell transplantation and sibling/non-related transplantation. Since 2022, the center has also accumulated experience in CAR-T cell therapy, which has become a treatment option for relapsed/refractory lymphoma and acute lymphoblastic leukemia, as well as clinical trials for CAR-T cell therapies with novel mechanisms for multiple myeloma. Hematopoietic stem cell transplantation and cell therapies are the ultimate treatment method that gives recurrent/intractable hematologic malignancy patients hope for complete cure. However, it is also a treatment technique with high risk, in which the infrastructure of an organically organized transplantation center and extensive experience of medical professionals are important. The Hematopoietic Stem Cell Transplantation Center at Seoul National University Cancer Hospital meets all these requirements.